

Philip Marder

Pharmaceutical Research Scientist
Flow Cytometry Consultant

November, 2007



- Recognized expert and opinion leader for use of flow cytometry in pharmaceutical R & D. 30+ years experience. Presented research overviews at international conferences.
- Strategically involved in multiple layers of the drug development process (discovery, product development, and clinical trials).
- Externally networked and collaborated with academic, industrial, and vendor colleagues in the discipline.
- Helped develop flow cytometry as a key technology in the burgeoning field of drug activity biomarker analysis for lab animal testing and pharmaceutical clinical trials.
- Served as a Group Leader, for six scientists at Lilly doing biomarker research.
- Identified and introduced multiplexed bead technology (Luminex) to Lilly and helped further develop the technology through corporate partnerships.
- Technically proficient with 4 major product platforms (BD, Coulter, DAKO-Cytomation, and Luminex). Training certificates on file.

For a more detailed summary visit:

http://www.redramconsulting.com/Marder_short_bio.htm

Philip Marder

11/1/2007

Address: 7311 Brackenwood Cir S
Indianapolis, Indiana 46260

Telephone: Cell: (317) 437-7388
Home: (317) 257-8605

Email: phil@redramconsulting.com

Professional Experience:

2007 - Present	Consultant Redram Consulting, LLC Indianapolis, Indiana 46260
2004 - 2007	Research Advisor Lilly Research Laboratories Indianapolis, Indiana 46285
1998 - 2004	Principal Research Scientist Lilly Research Laboratories Indianapolis, Indiana 46285
1993 - 1997	Senior Biologist Lilly Research Laboratories Indianapolis, Indiana 46285
1986 - 1993	Associate Senior Immunologist Lilly Research Laboratories Indianapolis, Indiana 46285

Professional Affiliations:

International Society for Analytical Cytology (ISAC)
American Association of Pharmaceutical Scientists (AAPS)
Society for Bimolecular Science
Great Lakes Int. Imaging and Flow Cytometry Assoc., Inc.
Indy Flow Users Group

Honors:

Phi Beta Kappa

Lilly Research Laboratories President's Research Award
"ex vivo pharmacodynamic measurements"

Lilly Research Laboratories President's Research Award
Multiplexed analyte measurements (Luminex)

Education:

The Ohio State University, Columbus, Ohio, Master of Science, 1973

The Ohio State University, Columbus, Ohio, Bachelor of Science, cum laude, 1970.

Publications (1–48):

Bibliography

1. Bowers, R. K., Marder, P., Green, L. J., Horn, C. L., Faber, A. L., and Thomas, J. E. A Platelet Biomarker for Assessing Phosphoinositide 3-Kinase Inhibition during Cancer Chemotherapy. *Molec Cancer Therapeutics*, 6: 2600-2607, 2007.
2. Marder, P., Green, L. J., Flow Cytometry Provides a Powerful Tool for Measuring Molecular Target Inhibition of New Drugs in the Clinic. *Amer Drug Discovery*, July, 2007.
3. Green, L. J., Marder, P., Ray, C., Cook, C. A., Jaken, S., Musib, L. C., Herbst, R. S., Carducci, M., Britten, C. D., Basche, M., Eckhardt, S. G., and Thornton, D. Development and validation of a drug activity biomarker that shows target inhibition in cancer patients receiving enzastaurin, a novel protein kinase C-beta inhibitor. *Clin Cancer Res*, 12: 3408-3415, 2006.
4. Sandler, A., Gordon, M., De Alwis, D. P., Pouliquen, I., Green, L., Marder, P., Chaudhary, A., Fife, K., Battiato, L., Sweeney, C., Jordan, C., Burgess, M., and Slapak, C. A. A Phase I trial of a potent P-glycoprotein inhibitor, zosuquidar trihydrochloride (LY335979), administered intravenously in combination with doxorubicin in patients with advanced malignancy. *Clin Cancer Res*, 10: 3265-3272, 2004.
5. Rubin, E. H., de Alwis, D. P., Pouliquen, I., Green, L., Marder, P., Lin, Y., Musanti, R., Grospe, S. L., Smith, S. L., Toppmeyer, D. L., Much, J., Kane, M., Chaudhary, A., Jordan, C., Burgess, M., and Slapak, C. A. A phase I trial of a potent P-glycoprotein inhibitor, Zosuquidar.3HCl trihydrochloride (LY335979), administered orally in combination with doxorubicin in patients with advanced malignancies. *Clin Cancer Res*, 8: 3710-3717, 2002.
6. Green, L. J., Marder, P., and Slapak, C. A. Modulation by LY335979 of P-glycoprotein function in multidrug-resistant cell lines and human natural killer cells. *Biochem Pharmacol*, 61: 1393-1399, 2001.
7. Stanislaus, D., Yang, X., Liang, J. D., Wolfe, J., Cain, R. L., Onyia, J. E., Falla, N., Marder, P., Bidwell, J. P., Queener, S. W., and Hock, J. M. In vivo regulation of apoptosis in metaphyseal trabecular bone of young rats by synthetic human parathyroid hormone (1-34) fragment. *Bone*, 27: 209-218, 2000.
8. Green, L. J., Marder, P., Mann, L. L., Chio, L. C., and Current, W. L. LY303366 exhibits rapid and potent fungicidal activity in flow cytometric assays of yeast viability. *Antimicrob Agents Chemother*, 43: 830-835, 1999.
9. Green, L. J., Marder, P., Um, S. L., Jakubowski, J. A., and Lawrence, J. B. Quantitative detection of platelet GPIIb-IIIa receptor antagonist activity using a flow cytometric method. *J Clin Lab Anal*, 12: 191-196, 1998.

Publications (continued)

10. van Pelt, J. P., de Jong, E. M., van Erp, P. E., Mitchell, M. I., Marder, P., Spaethe, S. M., van Hooijdonk, C. A., Kuijpers, A. L., and van de Kerkhof, P. C. The regulation of CD11b integrin levels on human blood leukocytes and leukotriene B₄-stimulated skin by a specific leukotriene B₄ receptor antagonist (LY293111). *Biochem Pharmacol*, 53: 1005-1012, 1997.
11. Sofia, M. J., Floreancig, P., Bach, N., Baker, S. R., Nelson, K., Sawyer, J. S., Baldwin, R., Cockerham, S. L., Fleisch, J. H., Froelich, L. L., Jackson, W. T., Marder, P., Roman, C. R., Saussy, D. L., Jr., Silbaugh, S. A., Spaethe, S. M., and Stengel, P. W. The discovery of LY293111, a novel, potent and orally active leukotriene B₄ receptor antagonist of the biphenylphenol class. *Adv Exp Med Biol*, 400A: 381-386, 1997.
12. Tonkinson, J. L., Marder, P., Andis, S. L., Schultz, R. M., Gossett, L. S., Shih, C., and Mendelsohn, L. G. Cell cycle effects of antifolate antimetabolites: implications for cytotoxicity and cytostasis. *Cancer Chemother Pharmacol*, 39: 521-531, 1997.
13. Marder, P., Spaethe, S. M., Froelich, L. L., Cerimele, B. J., Petersen, B. H., Tanner, T., and Lucas, R. A. Inhibition of ex vivo neutrophil activation by oral LY293111, a novel leukotriene B₄ receptor antagonist. *Br J Clin Pharmacol*, 42: 457-464, 1996.
14. O'Leary, E. C., Marder, P., and Zuckerman, S. H. Glucocorticoid effects in an endotoxin-induced rat pulmonary inflammation model: differential effects on neutrophil influx, integrin expression, and inflammatory mediators. *Am J Respir Cell Mol Biol*, 15: 97-106, 1996.
15. Allen, D. L., Hoffman, W. P., Marder, P., Matchett, M. R., Leiter, P. A., Abbott, D. L., and Wolff, R. K. The effects of LY293111Na, a leukotriene B₄ receptor antagonist, on the pulmonary neutrophilia and CD11b expression caused by inhalation of a leukotriene B₄ aerosol in rhesus monkeys. *J Pharmacol Exp Ther*, 277: 341-349, 1996.
16. Sofia, M. J., Nelson, K., Herron, D. K., Goodson, T., Froelich, L. L., Spaethe, S. M., Marder, P., Roman, C. R., and Fleisch, J. H. 2-Alkyl-4-ethyl-5-[6-methyl-6-(2H-tetrazol-5Y)heptyloxy]phenol leukotriene B₄ receptor antagonists. *Bioorgan.Med.Chem.Let.*, 5: 1995-2000, 1995.
17. Sawyer, J. S., Bach, N. J., Baker, S. R., Baldwin, R. F., Borromeo, P. S., Cockerham, S. L., Fleisch, J. H., Floreancig, P., Froelich, L. L., Jackson, W. T., Marder, P., Palkowitz, J. A., Roman, C. R., Saussy, D. L., Schmittling, E. A., Silbaugh, S. A., Spaethe, S. M., Stengel, P. W., and Sofia, M. J. Synthetic and structure-activity studies on acid-substituted 2-arylphenols - discovery of 2-[2-propyl-3-[3-[2-ethyl-4-(4-fluorophenyl)-5-hydroxyphenoxy]-propoxy]phenoxy]benzoic acid, a high-affinity leukotriene b-4 receptor antagonist. *JOURNAL.OF MEDICINAL.CHEMISTRY.*, 38: 4411-4432, 1995.
18. Marder, P., Sawyer, J. S., Froelich, L. L., Mann, L. L., and Spaethe, S. M. Blockade of human neutrophil activation by 2-[2-propyl-3-[3-[2-ethyl-4-(4-fluorophenyl)-5-hydroxyphenoxy]propoxy]phenoxy]benzoic acid (LY293111), a novel leukotriene B₄ receptor antagonist. *Biochem Pharmacol*, 49: 1683-1690, 1995.

Publications (continued)

19. Vlahos, C. J., Matter, W. F., Brown, R. F., Traynor-Kaplan, A. E., Heyworth, P. G., Prossnitz, E. R., Ye, R. D., Marder, P., Schelm, J. A., Rothfuss, K. J., and et al. Investigation of neutrophil signal transduction using a specific inhibitor of phosphatidylinositol 3-kinase. *J Immunol*, 154: 2413-2422, 1995.
20. Sawyer, J. S., Schmittling, E. A., Bach, N. J., Baker, S. R., Froelich, L. L., Saussy, D. L., Marder, P., and Jackson, W. T. Structural analogues of LY292728, a highly potent xanthone dicarboxylic acid leukotriene B4 receptor antagonist: spatial positioning of the secondary acid group. *Bioorgan.Med.Chem.Let.*, in press: 0, 1994.
21. Mohamadi, F., Spees, M. M., Staten, G. S., Marder, P., Kipka, J. K., Johnson, D. A., Boger, D. L., and Zarrinmayeh, H. Total synthesis and biological properties of novel antineoplastic (chloromethyl)furanoidolines: an asymmetric hydroboration mediated synthesis of the alkylation subunits. *J Med Chem*, 37: 232-239, 1994.
22. Sawyer, J. S., Baldwin, R. F., Sofia, M. J., Floreancig, P., Marder, P., Saussy, D. L., Jr., Froelich, L. L., Silbaugh, S. A., Stengel, P. W., Cockerham, S. L., and et al. Biphenyl-substituted xanthenes: highly potent leukotriene B4 receptor antagonists. *J Med Chem*, 36: 3982-3984, 1993.
23. Sofia, M. J., Floreancig, P., Bach, N. J., Baker, S. R., Cockerham, S. L., Fleisch, J. H., Froelich, L. L., Jackson, W. T., Marder, P., Roman, C. R., and et al. o-phenylphenols: potent and orally active leukotriene B4 receptor antagonists. *J Med Chem*, 36: 3978-3981, 1993.
24. Marder, P. Ligand interactions with the RGD recognition site alter binding of GPIIb-IIIa reactive monoclonal antibody to human platelets. *Biochem Biophys Res Commun*, 195: 799-806, 1993.
25. Sofia, M. J., Saussy, D. L., Jackson, W. T., Marder, P., Silbaugh, S. A., Froelich, L. L., Cockerham, S. L., and Stengel, P. W. Ortho-alkoxyphenol leukotriene B4 receptor antagonists: effect of a chroman carboxylic acid. *Bioorgan.Med.Chem.Let.*, 2: 1675-1680, 1992.
26. Marder, P., Schultz, R. M., Spaethe, S. M., Sofia, M. J., and Herron, D. K. Flow cytometric evaluation of the effects of leukotriene B4 receptor antagonists (LY255283 and SC-41930) on calcium mobilization and integrin expression of activated human neutrophils. *Prostaglandins Leukot Essent Fatty Acids*, 46: 265-270, 1992.
27. Schultz, R. M., Marder, P., Spaethe, S. M., Herron, D. K., and Sofia, M. J. Effects of two leukotriene B4 (LTB4) receptor antagonists (LY255283 and SC-41930) on LTB4-induced human neutrophil adhesion and superoxide production. *Prostaglandins Leukot Essent Fatty Acids*, 43: 267-271, 1991.
28. Hatfield, S. M., Rodgers, G. H., Marder, P., and Roehm, N. W. Patterns of lymphokine production by primary antigen-specific/MHC restricted murine helper T cell clones. *Immunol Invest*, 20: 55-73, 1991.

Publications (continued)

29. Marder, P., Maciak, R. S., Fouts, R. L., Baker, R. S., and Starling, J. J. Selective cloning of hybridoma cells for enhanced immunoglobulin production using flow cytometric cell sorting and automated laser nephelometry. *Cytometry*, 11: 498-505, 1990.
30. Starling, J. J., Cote, R. J., Marder, P., Borowitz, M. J., and Johnson, D. A. Tissue distribution and cellular location of the antigens recognized by human monoclonal antibodies 16.88 and 28A32. *Cancer Res*, 48: 7273-7278, 1988.
31. Starling, J. J., Hinson, N. A., Marder, P., Maciak, R. S., Laguzza, B. C., Corvalan, J. R., and Smith, W. Development of a dual label fluorescence technique that can be utilized to elucidate the mechanism of action of monoclonal antibody-drug conjugates. *Cancer Res*, 48: 6211-6216, 1988.
32. Butler, L. D., Browne, C. P., Layman, N. K., Riedl, P., Tang, J., Marder, P., DeLong, D., Manetta, J., Bobbitt, L., Strnad, J., and et al. In vivo effects of recombinant human interleukin 2 on antitumor and antiviral natural immunity in induced or natural murine immunodeficiency states. *Cancer Res*, 48: 6081-6089, 1988.
33. Bumol, T. F., Marder, P., DeHerdt, S. V., Borowitz, M. J., and Apeltgren, L. D. Characterization of the human tumor and normal tissue reactivity of the KS1/4 monoclonal antibody. *Hybridoma*, 7: 407-415, 1988.
34. Zuckerman, S. H., Schreiber, R. D., and Marder, P. Reactivation of class II antigen expression in murine macrophage hybrids. *J Immunol*, 140: 978-983, 1988.
35. Marder, P., Apeltgren, L. D., and Bumol, T. F. Comparative analysis of monoclonal antibody-drug conjugate binding by flow cytometry. *J Immunol Methods*, 96: 165-170, 1987.
36. Butler, L. D., DeRiso, P. E., Marder, P., and Scheetz, M. E. In vivo expression and regulation of murine IL 2 receptors after antigen sensitization. *J Immunol*, 138: 470-477, 1987.
37. Zuckerman, S. H., Tang, J., Marder, P., Butler, L. D., and Carlson, D. G. Establishment and characterization of murine macrophage hybrids. *Cell Immunol*, 103: 207-215, 1986.
38. Marder, P. PROLIF: a computer program for calculation and comparison of cultured lymphocyte proliferation. *Comput Methods Programs Biomed*, 23: 31-36, 1986.
39. Tang, J., DeLong, D. C., Butler, L. D., Marder, P., and Ades, E. W. Murine thymocytes mediate a natural killer-like activity against herpes virus-infected target cells but not YAC-1 target cells. *Scand J Immunol*, 24: 115-118, 1986.
40. Tang, J., DeLong, D. C., Marder, P., Butler, L. D., and Ades, E. W. Identification of functional subpopulations of murine natural killer cells based on their cell surface asialo GM1 phenotype. *Cell Immunol*, 96: 386-397, 1985.
41. Lukasewycz, O. A., Prohaska, J. R., Meyer, S. G., Schmidtke, J. R., Hatfield, S. M., and Marder, P. Alterations in lymphocyte subpopulations in copper-deficient mice. *Infect Immun*, 48: 644-647, 1985.

Publications (continued)

42. Marder, P. and Schmidtke, J. R. Cyclosporin A inhibits helper/inducer surface antigen expression on activated human lymphocytes. *Int J Immunopharmacol*, 7: 165-175, 1985.
43. Marder, P. Interleukin-2 determinations using an IBM-PC. *CAL*, 3: 3, 1984.
44. Redlich, P. N., Leapman, S. B., Marder, P., Schmidtke, J., Smith, E. J., Fineberg, N., and Filo, R. S. Evaluation of lymphocyte subsets and suppressor cell function in long-term renal transplant recipients. *Transplant Proc*, 16: 1555-1557, 1984.
45. Marder, P., Hinson, A., Russo, C., Ferrone, S., and Ades, E. Heterogeneity of human peripheral blood mononuclear cells detected by monoclonal antibodies to monomorphic determinants of human Ia antigens. *Immunobiology*, 167: 483-494, 1984.
46. Ades, E. W., Hinson, A., Marder, P., and Butler, L. D. Potentiation of Leu 11 + natural cytotoxicity by human interleukin 2. *Clin Immunol Immunopathol*, 32: 119-121, 1984.
47. Marder, P. and Schmidtke, J. R. Effects of methylprednisolone on concanavalin A-induced human lymphocyte blastogenesis: a comparative analysis by flow cytometry, volume determination and 3H-thymidine incorporation. *Immunopharmacology*, 6: 155-166, 1983.
48. Phadke, K., Nanda, S., Marder, P., and Carlson, D. G. Release of chondrocyte-stimulating factor by rabbit peritoneal macrophages. *Clin Exp Immunol*, 43: 408-416, 1981.

Abstracts:

1. P. Marder. Quantifying intracellular signaling events using flow cytometry provides a powerful tool for measuring in vivo target inhibition of drug candidates. Society for Biomolecular Science. Platform presentation. Montréal. April, 2007.
2. P. Marder. Use of Flow Cytometry for Biomarker Analysis in Pre-clinical and Clinical Phases of New Drug Development. Society for Biomolecular Science. Platform presentation, Geneva. Sept. 12, 2005.
3. P. Marder. Use of Flow Cytometry for In Vivo Biomarker Analysis During Drug Development. IBC Conference . Platform presentation, Boston. August, 2005.
4. P. Marder. Use of Flow Cytometry for Biomarker Analysis during Clinical Evaluation of Potential New Pharmaceutical Agents. Great Lakes Imaging and Flow Cytometry Conference. Platform presentation, Windsor, Ontario, Oct 24, 2004.
5. P. Marder and L. Green. Use of Flow Cytometry for Biomarker Analysis during Clinical Evaluation of Potential New Pharmaceutical Agents. XXII Congress of the International Society for Analytical Cytology. 2004.
6. L. Green, C. Ray, S. Jaken, C. Cook, R. Campbell, I. Gourley, D. Thornton, and P. Marder. Development and application of Methods for Intracellular phospho-Protein Detection for Clinical Biomarker Analysis in Drug Development. XXII Congress of the International Society for Analytical Cytology. 2004.
7. L. Green and P. Marder . Novel DcR3 (TR6) Analog Inhibits Fas ligand Induced Apoptosis of Target Cells in Whole Blood. XXI Congress of the International Society for Analytical Cytology. 2002.
8. L. Green and P. Marder . CD95 Expression and Fas Ligand Induced Apoptosis of Jurkat T Cells and Human Lymphocytes. Great Lakes Imaging and Flow Cytometry Conference. 2001.
9. L. Green, T. Hunte, and P. Marder. An intracellular cytokine assay for quantitative detection of TNFa in Human monocytes. Great Lakes Imaging and Flow Cytometry Conference. 2000.
10. L. Green, F. Chadwell, M. Anania, L. Mann, J. Lee, and P. Marder. Flow Cytometric Cell Sorting - An Indispensable Tool for Drug Discovery. XX Congress of the International Society for Analytical Cytology. 2000.
11. L. Green, C. Slapak and P. Marder. Development Of A Flow Cytometric Surrogate Efficacy Assay For Clinical Evaluation Of LY335979, A Potent New MDR Modulator. XIX Congress of the International Society for Analytical Cytology. 1998.
12. P. Marder, L. Green. Blockade Of Substrate Efflux in Multidrug Resistant Human Cell Lines by LY335979, A Potent, New Pgp Modulator. XIX Congress of the International Society for Analytical Cytology. 1998.

Abstracts (continued)

13. L.J. Green, L.L. Mann, W. L. Current and P. Marder. Single Cell Sorting Confirms the Relationship Between Increased Membrane Permeability and Fungicidal Activity of the Echinocandin-B Analog, LY30336. 97th General Meeting for the American Society for Microbiology. 1997.
14. P. Marder, L.J. Green, S.L. Um, J.A. Jakubowski and J. B. Lawrence. Analysis Of Fibrinogen Binding To Platelets And Quantitative Detection Of Platelet IIb/IIIa Receptor Antagonist Activity Using Flow Cytometric Methods. 36th American Society for Cell Biology Annual Meeting. 1996.
15. L.J. Green, L.L. Mann and P. Marder. Optimization Of Sample Preparation And Data Analysis For Immunophenotyping Proficiency Surveys. Great Lakes Imaging and Flow Cytometry Conference. 1996.
16. K.Y. Hui, E. Angleton, R. Shuman, C. Campbell, P. Marder, C. Reidy. Pharmacological properties of thrombin receptor antagonists on isolated human platelets. Fourteenth American Peptide Symposium. 1995.
17. P. Marder, C. Reidy, E. Angleton, R. Shuman, C. Campbell and K.Y. Hui. Thrombin receptor antagonists differentially inhibit activation functions of human platelets. Experimental Biology 95. Abstract No. 3261. 1995.
18. S.M. Spaethe, P Marder, L.L. Froelich, B.H. Petersen, T.W. Croghan, R.A. Lucas, T. Tanner and J.S. Sawyer. Pharmacologic efficacy of LY293111, a potent orally active leukotriene B4 (LTB4) receptor antagonist, in humans. XIIth IUPHAR Congress. 1994.
19. J.S.Sawyer, P.S. Bottomeo, L.L. Froelich, D.L. Saussy, P. Marder, W.T. Jackson and S. M. Spaethe. Structural analogues of LY293111, a potent, orally active diaryl ether carboxylic acid leukotriene B4 receptor antagonist. Twenty-fourth National Medicinal Chemistry Symposium. 1994.
20. P. Marder, L. Froelich, B. Petersen, J. Sawyer, T. Croghan, R. Lucas, T. Tanner and S. Spaethe. Discovery and clinical tracking of a potent and selective anti-inflammatory agent using flow cytometric methods. XVII Congress of the International Society for Analytical Cytology. 1994.
21. P. Marder. Discovery and development of a novel anti-inflammatory agent using flow cytometric technology. Coulter Midwest Cytometry Users Meeting. 1994.
22. F. Mohamadi, M.M. Spees, G.S. Staten, P. Marder, J.K. Kipka, D.A. Johnson, D.L. Boger and H. Zarrinmayeh. Antineoplastic Chloromethylfuranoidolines. 206th National American Chemical Society Meeting. 1993.
23. M.J. Sofia, P. Floreancig, N. Bach, S.R. Baker, K. Nelson, J.S. Sawyer, S.L. Cockerham, J.H. Fleisch, L.L. Froelich, W.T. Jackson, P. Marder, C.R. Roman, D.L. Saussy Jr., S.A. Silbaugh, S.M. Spaethe and P.W. Stengel. The discovery of LY293111, a novel, potent and orally active leukotriene B4 receptor antagonist of the biphenylphenol class. 3rd Int. Conference on Eicosanoids and Other Bioactive Lipids in Cancer, Inflammation and Radiation Injury. 1993.

Abstracts (continued)

24. J. Sawyer, R. Baldwin, P. Borromeo, S. Cockerham, J. Fleisch, P. Floreancig, L. Froelich, W. Jackson, P. Marder, J. Palkowitz, C. Roman, D. Saussy, Jr., S. Silbaugh, M. Sofia, S. Spaethe, and P. Stengal. Biphenylphenol/biaryl ether Leukotriene B4 receptor antagonists: the discovery of LY293111 (2-[2-propyl-3-[3-[2-ethyl-4-(4-fluorophenyl)-5-hydroxyphenoxy]propoxy]phenoxy]benzoic acid sodium salt). 1993 FASEB Summer Research Conferences: Cytokines and Lipid Mediators in Regulation of Cell Function. 1993.
25. K. Hui, C. Reidy, P. Marder, and E. Angleton. Peptidyl ligands of thrombin receptor: Activation and inhibition of human platelet thromboxane production and GMP-140 expression. Thirteenth American Peptide Symposium. 1993.
26. P. Marder. Epitope masking of fibrinogen receptors on activated human platelets. XVI Congress of the International Society for Analytical Cytology. 1993.
27. L. Stramm, P. Marder, C. Johnston, P. Ober, and W. Heath. Modulation of Retinal Capillary Endothelial Cell Protease Activity by Protein Kinase C. ADA/IDF Meeting. 1991.
28. P. Marder, R. Schultz, S. Spaethe, M. Sofia, and D. Herron. Flow Cytometric Evaluation of Leukotriene B4 (LTB4) Receptor Antagonists (LY255283 and SC-41930) on Chemoattractant-induced Human Neutrophil Activation. FASEB National Meeting. 1991.
29. P. Marder, R. S. Maciak, R. L. Fouts, and J. J. Starling. Flow Cytometric Cloning of Hybridoma Cells for Enhanced Immunoglobulin Production.. International Conference on Analytical Cytology XIV. 1990.
30. P. Marder. An automated system for immunofluorescence sample preparation used in flow cytometry. Midwest Flow Cytometry Users Meeting. 1989.
31. S. Hatfield, G. Rogers, P. Marder and N. Roehm. Characterization of lymphokine production by primary antigen-specific/MHC restricted murine helper T cell clones. FASEB National Meeting. 1989.
32. P. Marder and R. Greene. An automated system for immunofluorescence sample preparation used in flow cytometry. XIII International Meeting of the Society for Analytical Cytology. 1988.
33. P. Marder, N.A. Hinson, R. Maciak, B. Laguzza, and J. Starling. Simultaneous fluorescence detection of immunoglobulin and drug on human tumor cells incubated with monoclonal antibody-drug conjugates. Second Conference on Immunity to Cancer. 1987.
34. N.A. Hinson, P. Marder, R. Maciak, B. Laguzza, and J. Starling. Differential endocytosis of monoclonal antibody-vinca alkaloid immunoconjugates determined by a dual fluorescence technique. Second Conference on Immunity to Cancer. 1987.

Abstracts (continued)

35. T.F. Bumol, B.C. Laguzza, S.V. Deherdt, A.L. Baker, P. Marder, C.L. Nichols, and L.D. Apelgren. KS1/4-4-desacetyl vinblastine- 3-carboxhydrazide (KS1/4-DAVLB-Hydrazide); preclinical studies on a monoclonal antibody drug conjugate for site-directed therapy of human monoclonal antibody-vinca alkaloid immunoconjugates determined by a dual fluorescence technique. Second Conference on Immunity to Cancer. 1987.
36. P. Marder. Custom EASY-88 applications: Simplified Data Directory Maintenance and Automated Data Reduction Techniques. Coulter Immunology/Cytometry Conference. 1986.
37. L.D. Butler, P.E. DeRiso, P. Marder, and M.E. Scheetz. In vivo interleukin-2 receptor expression following immunization- modulation by immunotherapeutic and pharmacologic agents. UCLA Symposia on Molecular and Cellular Biology. 1987.
38. P. Marder, L. Apelgren, and T. Bumol. Comparative analysis of monoclonal antibody-drug conjugate binding to human tumor cells by flow cytometry. International Conference for Analytical Cytology XI. 1985.
39. D.A. Johnson, M.C. Culwell, B.C. Laguzza, P. Marder, and C.L. Nichols. Non-specific reactivity of murine monoclonal antibodies (MoABs) and MOAB-drug conjugates with human and monkey PMNs. UCLA Symposia on Molecular and Cellular Biology. 1986.
40. S.H. Zuckerman, P. Marder, and D.G. Carlson. Establishment and characterization of murine macrophage hybrid cell lines. American Society for Cell Biology 25th Annual Meeting. 1985.
41. P. Marder, J. Tang, and D. DeLong. Functional subpopulations of murine natural killer cells based on quantitative surface antigen expression of asialo GM-1. EPICS Flow Cytometry Users Meeting. 1984.
42. R. Weller, P. Marder, A. Hinson, S. Ferrone, E. Ades, and M.R. Goodman. Abnormal antigenic expression on human mononuclear cells in sarcoid patients using flow cytometric analysis. National Meeting of the American College of Chest Physicians. 1984.
43. E.W. Ades, N.A. Hinson, P. Marder, and L.D. Butler. Human Leu-11a positive natural cytolytic cells are potentiated by human purified IL-2. UCLA Symposia on Molecular and Cellular Biology. 1984.
44. M. Culwell, P. Marder, and E.W. Ades. Generation of a human lymphoid cell line expressing T cytotoxic/suppressor cell antigens and functional natural killer (NK) activity. FASEB National Meeting. 1983.
45. P. Marder and J.R. Schmidtke. Cyclosporin A preferentially inhibits helper cell proliferation in the presence of suppressor cells. FASEB National Meeting. 1983.
46. O.A. Lukasewycz, J.R. Prohaska, J.R. Schmidtke, S.M. Hatfield, P. Marder, and S.B. Meyer. Alterations in lymphoid subpopulations and mitogen reactivity in copper deficient mice. FASEB National Meeting. 1982.

Abstracts (continued)

47. P. Marder and J.R. Schmidtke. Modification of surface antigen expression of human T lymphocytes following culture with mitogens and methylprednisolone. FASEB National Meeting. 1982.
48. D.G. Carlson, P. Marder, Y.L. Chang, and R.M. Schultz. The comparative effects of macrophages exposed to interferon (IF) or IF inducers on tumor cell growth and lymphoproliferation. RES National Meeting. 1980.
49. P. Marder, Y.L. Chang, and D.G. Carlson. Tumor cell cytostasis and inhibition of lymphocyte blastogenesis by macrophages treated with frentizole. RES National Meeting. 1980.
50. D.G. Carlson, Y. Chang, and P. Marder. The differential effects of frentizole and other immunoregulators on the blastogenic response of B and T lymphocyte enriched populations. RES National Meeting. 1979.
51. M.E. Scheetz, L.W. Hartley, D.G. Carlson, and P. Marder. The effects of human and murine interferons on antibody-complement mediated cytotoxicity, lectin stimulation of lymphocytes, and murine macrophage erythrophagocytosis. RES National Meeting. 1978.
52. V. Kalra, D.G. Carlson, R.J. Herman, P. Marder, Y. Chang, and M.R. Schinitsky. Differential effects of the vinca alkaloids on the RES in mice. RES National Meeting. 1978.

Patents:

1. United States Patent : "Selective Cloning for High Monoclonal Antibody Secreting Hybridomas". : P. Marder and R. Maciak. U.S. Patent Number 5,264,341 issued 11/23/93.

Internet Citations:

1. Go With the Flow: Sorting Cells and Other Small Things.
<http://www.dddmag.com/ShowPR.aspx?PUBCODE=016&ACCT=1600000100&ISSUE=0409&RELTYPE=PR&ORIGRELTYPE=CEL&PRODCODE=00000000&PRODL ETT=B>
2. Use Of Flow Cytometry For Biomarker Analysis in Pre-clinical and Clinical Phases of New Drug Development.
<http://www.sbsonline.org/sbscon/2005/speakers/050315133556.php>